The PCSK9 monoclonal antibody evolocumab (Repatha, Repatha Repatha Amgen) was well tolerated and effectively lowered LDL cholesterol by 38% compared with placebo in a randomized controlled trial in ...

The monoclonal antibody evolocumab produced highly significant reductions in low-density lipoprotein cholesterol, the "bad cholesterol," as an add-on to statins in all treatment groups, according to ...

NEW ORLEANS -- Adding the PCSK9 inhibitor evolocumab (Repatha) to stable lipid-lowering therapy reduced major adverse cardiac events (MACE) in patients with atherosclerosis or high-risk diabetes, but ...

Evolocumab, one of the new targeted PCSK9 inhibitor drugs that has been shown to dramatically lower levels of low-density lipoprotein (LDL), or “bad” cholesterol, also significantly lowers the risk of ...

BRUSSELS, BELGIUM — Evolocumab (Repatha, Amgen), one of the proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors, is the first of these agents approved in Europe for the treatment of patients ...

WASHINGTON, DC (UPDATED)—The eagerly anticipated final results of FOURIER, a large clinical trial testing evolocumab (Repatha, Amgen) in patients with stable atherosclerotic cardiovascular disease, ...

(HealthDay News) — Evolocumab shows promise for patients with heterozygous or homozygous familial hypercholesterolemia, according to two studies published online October 1 in The Lancet. Frederick J.

Data presented at the American College of Cardiology’s 63rd Annual Scientific Session showed that evolocumab (Amgen) significantly reduced low-density lipoprotein (LDL) cholesterol as an add-on to ...

Results from higher-risk subgroups could help clinicians target this cholesterol-fighting therapy to patients who most need it, authors of one abstract say. From the start, the debate about the ...

Please provide your email address to receive an email when new articles are posted on . Evolocumab in addition to standard of care for the treatment of hypercholesterolemia was shown to have ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. WASHINGTON — Findings from two trial demonstrate that ...

The PCSK9 inhibitor evolocumab (Repatha, Amgen) is far too expensive to make economic sense for the healthcare system and private payers, according to the results of yet another cost-effectiveness ...